Systemic Amyloidosis Therapeutic Market Expected To Reach $8.88 Billion By 2030 As Growth Accelerates At 9.4% CAGR
Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.
#Systemic Amyloidosis Therapeutic Market Size And Revenue Forecast Through 2030
The systemic amyloidosis therapeutic market size has shown strong expansion in recent years. It is projected to increase from $5.67 billion in 2025 to $6.2 billion in 2026, achieving a compound annual growth rate (CAGR) of 9.2%. The historical growth of this market was driven by factors such as the past underdiagnosis of amyloidosis, the reliance on chemotherapy regimens, the expansion of hematology treatment centers, heightened rare disease awareness, and the early incorporation of proteasome inhibitors.
The therapeutic market for systemic amyloidosis is projected to experience robust expansion over the coming years. This market is set to reach $8.88 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 9.4%. This anticipated growth during the forecast period stems from several factors, including an increase in rare disease diagnosis rates, the proliferation of targeted biologic medications, a rise in approvals for gene silencing therapies, the expansion of specialized clinic networks, and more robust incentives for orphan drugs. Key trends anticipated within this period encompass targeted amyloid protein stabilizer drugs, gene silencing therapies for amyloidosis, treatments based on monoclonal antibodies, combination regimen protocols, and organ-specific supportive drug strategies.
Download A Free Sample Report For Comprehensive Market Insights:
#Systemic Amyloidosis Therapeutic Market Growth Drivers And Industry Catalysts
The increasing application of personalized medicine methodologies is projected to stimulate the growth of the systemic amyloidosis therapeutic market in the coming years. Personalized medicine represents a medical strategy that customizes treatment and prevention plans based on an individual’s genetic makeup, biomarkers, and distinct disease characteristics. Demand for personalized medicine is escalating due to advancements in genomic and biomarker technologies, which allow clinicians to precisely identify disease drivers and tailor treatments, thereby enhancing efficacy and reducing adverse effects for individual patients. The integration of personalized medicine heightens the need for systemic amyloidosis therapeutics, as patients with systemic amyloidosis exhibit diverse amyloid subtypes (e.g., AL, ATTR) and genetic variations. Therefore, effective treatment necessitates therapies specifically formulated to target the patient’s unique disease profile, ensuring maximum efficacy and minimal side effects. For instance, in April 2025, the US-based nonprofit advocacy and educational organization, Personalized Medicine Coalition (PMC), reported that in 2023, the FDA approved 16 new personalized treatments for rare disease patients, an increase from six in 2022. Consequently, the expanding adoption of personalized medicine approaches is fueling the growth of the systemic amyloidosis therapeutic market.
Systemic Amyloidosis Therapeutic Market Segment Analysis And Revenue Opportunities
The systemic amyloidosis therapeutic market covered in this report is segmented –
1) By Product Type: Small Molecule Drugs; Biologic Therapies; Monoclonal Antibodies; Chemotherapy Based Regimens; Targeted Therapies; Supportive Treatments
2) By Formulation: Tablets; Capsules; Injection
3) By Route of Administration: Oral; Intravenous; Subcutaneous
4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
5) By End User: Hospitals; Specialty Clinics; Specialty Pharmacies; Research and Academic Institutes; Other End Users
Subsegments:
1) By Small Molecule Drugs: Proteasome Inhibitors; Stabilizers of Transthyretin Protein; Amyloid Fibril Disruptors; Immunomodulatory Small Molecules
2) By Biologic Therapies: Recombinant Protein Therapies; Gene Silencing Biologic Agents; Plasma Derived Biologic Products
3) By Monoclonal Antibodies: Anti Amyloid Fibril Antibodies; Anti Light Chain Antibodies; Targeted Clearance Antibodies
4) By Chemotherapy Based Regimens: Alkylating Agent Based Regimens; Proteasome Inhibitor Based Chemotherapy; Combination Chemotherapy Protocols
5) By Targeted Therapies: Targeted Light Chain Suppression Therapies; Targeted Transthyretin Reduction Therapies; Organ Specific Targeted Treatments
6) By Supportive Treatments: Cardiac Supportive Therapies; Renal Supportive Therapies; Neurological Symptom Management Therapies; Nutritional and Palliative Care Therapies
#Systemic Amyloidosis Therapeutic Market Trends Influencing Long-Term Demand
Major companies operating in the systemic amyloidosis therapeutic market are concentrating on creating advanced targeted treatment approaches, including RNA interference-based therapies, to address the underlying genetic causes of protein misfolding disorders, curb disease progression, and improve long-term patient outcomes. RNA interference-based therapies function by selectively silencing disease-causing genes, thereby diminishing the production of harmful proteins responsible for systemic organ damage. For instance, in March 2025, Alnylam Pharmaceuticals, a US-based biotechnology company, launched AMVUTTRA. AMVUTTRA provides a targeted, disease-modifying treatment for adults with transthyretin amyloidosis with cardiomyopathy (ATTR-CM). Developed by Alnylam Pharmaceuticals, it is the first RNAI therapeutic shown to reduce cardiovascular death, hospitalizations, and urgent heart failure visits in this patient population. AMVUTTRA works by rapidly suppressing transthyretin production at the source, directly addressing the underlying cause of amyloid deposition. It demonstrates consistent benefits across cardiovascular outcomes, functional capacity, and quality of life.
Systemic Amyloidosis Therapeutic Market Leading Players Shaping Industry Direction
Major companies operating in the systemic amyloidosis therapeutic market are Johnson & Johnson Services Inc., Sanofi SA, Novartis Plc, AstraZeneca Plc, GSK Plc, Novo Nordisk A/S, Takeda Pharmaceutical Company Limited, Regeneron Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc., Ionis Pharmaceuticals, Arcturus Therapeutics Inc, Prothena Biosciences, Fortress Biotech Inc., Intellia Therapeutics Inc., Zentalis Pharmaceuticals Inc., BridgeBio Pharma Inc., Neurimmune AG, HaemaLogix Pty Ltd., Attralus Inc., and Oncopeptides AB.
Access The Complete Systemic Amyloidosis Therapeutic Market Report:
Systemic Amyloidosis Therapeutic Market Geographic Landscape: Which Region Dominates Industry Growth?
North America was the largest region in the systemic amyloidosis therapeutic market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the systemic amyloidosis therapeutic market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
